Invest ideasNews
30 Apr 2026, 19:16
WLD Comprehensive Technical Analysis: Detailed Review of April 30, 2026
WLD is consolidating at $0.25 within a downtrend, bearish indicators and $0.2375 support risk dominate. A cautious approach is recommended due to BTC correlation, short RR attractive.
30 Apr 2026, 19:12
Hoskinson warns clarity act could block new ADA rivals
🚨 Hoskinson warns the CLARITY Act could shut out new $ADA competition. The proposed law may favor big players while stifling innovation. Continue Reading: Hoskinson warns clarity act could block new ADA rivals The post Hoskinson warns clarity act could block new ADA rivals appeared first on COINTURK NEWS .
30 Apr 2026, 19:11
Ripple’s XRP Silent Surge: Volume Is Telling a Bigger Story
XRP’s market behaviour continues to witness a paradigm shift, given that trading volume across major exchanges is going through the roof despite price remaining at a standstill.
30 Apr 2026, 19:11
BAT address activity hit 6-year high, will price follow?
The Basic Attention Token (BAT) token extended its price decline below $0.10 on Thursday as selling pressure across cryptocurrencies halted the recent spike. All the top coins in the market, including Bitcoin and Ethereum, have shed gains as risk assets reacted to interest rate decisions and ongoing uncertainty in the US-Iran war. BAT, therefore, faces a potential downward spiral. Any recovery for the token’s price will hinge on what happens in the broader crypto market. However, could an ecosystem milestone involving a significant surge in on-chain activity help bulls? Basic Attention Token address activity explodes The BAT token remains off its all-time high reached in 2021, and is down 53% year-to-date. Sellers continue to dominate since the local top hit in early December 2025. The gains mirrored the surge in prices of privacy-focused coins, with Basic Attention Token rising as Zcash (ZEC), Monero (XM), Dash (DASH), and Decred (DCR), among others, pumped. Most of these coins have since shed much of the upside amid broader selling. But while momentum evades buyers, on-chain data indicates the platform has recorded its biggest daily jump in address activity in six years. Per Santiment, about 5,196 unique addresses interacted on the network following the setup of a DAO and the transfer of 73 million GUANO tokens. According to Santiment, this surge in unique address activity comes as the BAT community, contributors, and ambassadors embrace the project’s DAO initiative. This decentralized organization is focused on network governance, experimentation, and incentive alignment within the ecosystem. While the event signifies a notable engagement milestone, analysts caution that the spike is tied to a specific governance event rather than a spontaneous expansion in daily browser usage or advertising demand. "This wasn’t organic retail usage alone. It was a structural event that forced dormant or inactive wallets back on-chain all at once," the platform noted. BAT price outlook CoinMarketCap data shows BAT price hovers around $0.096, down 2.6% in the past 24 hours and 4% this past week. The Brave-linked token continues to face headwinds as it navigates a challenging broader market environment, and upside momentum is only likely to come amid fresh user growth and expanded real-world utility. Basic Attention Token chart by TradingView From a technical perspective, the $0.090 level serves as critical psychological support. Should the broader crypto market experience increased volatility, a failure to hold this support could invite further selling pressure. Meanwhile, bulls face immediate overhead resistance in the $0.10 to $0.13 range, where previous consolidation occurred before the latest slide. A sustained breakout above this level would be required to shift the short-term sentiment from bearish to neutral. If bulls reclaim control, the next supply zone hovers around $0.20-$0.22. The post BAT address activity hit 6-year high, will price follow? appeared first on Invezz
30 Apr 2026, 19:10
Bitcoin Miner MARA Holdings Signs $1.5B Deal for Ohio Gas Plant, Plans AI Data Center
MARA Holdings, Inc. signed a definitive agreement on Thursday in order to acquire Long Ridge Energy & Power LLC from FTAI Infrastructure Inc. (Nasdaq: FIP) for approximately $1.5 billion, adding a 505 MW natural gas power plant and more than 1,600 acres in Hannibal, Ohio. Key Takeaways: MARA Holdings agreed to buy Long Ridge Energy
30 Apr 2026, 19:10
FDA Approval and Fundraising: BioticsAI Founder Reveals the Reality of Building a Healthcare AI Startup
BitcoinWorld FDA Approval and Fundraising: BioticsAI Founder Reveals the Reality of Building a Healthcare AI Startup Building a healthcare AI startup demands more than just a great idea. It requires navigating strict regulations, securing funding, and maintaining team morale over long timelines. Robhy Bustami, co-founder and CEO of BioticsAI, knows this firsthand. His company develops an AI copilot for ultrasound that detects fetal abnormalities. In January, BioticsAI gained FDA approval, a critical milestone that allows the startup to deploy its technology in hospitals. This article explores the challenges and strategies behind FDA approval, fundraising, and building in healthcare. FDA Approval: A Milestone for BioticsAI BioticsAI received FDA approval in January, marking a turning point for the startup. This clearance enables the company to begin rolling out its AI copilot in hospitals. The FDA process is often seen as a black box, but Bustami emphasizes early engagement with regulators. Pre-submission meetings helped the team align on study design and expectations. This proactive approach reduced uncertainty and streamlined the approval process. From day one, BioticsAI integrated clinical validation, regulatory strategy, and product development. Instead of building first and figuring out regulation later, the team worked closely with clinicians. They collected large-scale datasets and ran structured clinical studies before submission. This rigorous approach was key to securing FDA approval. Fundraising Challenges in Healthcare AI Fundraising for a healthcare AI startup presents unique challenges. Investors often ask a simple question: What if the FDA says no? This risk makes it harder to secure funding. BioticsAI started scrappy, building an early prototype for under $100,000. That milestone helped them win Bitcoin World Startup Battlefield in 2023, bringing early visibility and credibility. Bustami notes that investors need to see a clear path to revenue. With FDA approval, BioticsAI can now generate revenue by deploying its technology in hospitals. This shift makes the startup more attractive to investors. The company plans to expand beyond obstetrics into broader areas of reproductive health. Building a Culture of Alignment Long timelines create a different kind of challenge: keeping the team motivated. At BioticsAI, building a culture of alignment across engineers, clinicians, and researchers was crucial. Bustami emphasizes the importance of celebrating small wins on the R&D side, from clinical studies to new healthcare partnerships. “Making sure everyone is completely aligned, even if it’s outside of their technical scope,” Bustami said, “constantly seeing wins on the R&D side.” This approach helps maintain morale when the biggest milestone is years away. Navigating Regulatory Red Tape Healthcare startups must navigate significant red tape. BioticsAI approached product development with FDA approval in mind from the start. This meant integrating regulatory strategy into every stage of development. The team worked closely with clinicians to ensure their product met clinical needs and regulatory standards. Early engagement with regulators through pre-submission meetings helped align expectations. This proactive approach reduced the risk of delays and rejection. Bustami advises other founders to not navigate the FDA process blindly. The Reality of Building in Healthcare Building in healthcare is a long game. It requires patience, discipline, and a willingness to operate in uncertainty. For founders willing to take that path, the reward isn’t just a successful company. It’s the chance to build something that genuinely changes how care is delivered. BioticsAI’s journey illustrates the importance of integrating regulatory strategy from the start. The company’s FDA approval opens doors to deployment and revenue generation. This milestone also validates the startup’s approach to building a healthcare AI product. Conclusion BioticsAI’s FDA approval marks a critical milestone for the healthcare AI startup. The company’s journey highlights the importance of early regulatory engagement, integrated product development, and team alignment. For founders building in healthcare, the path is long but rewarding. BioticsAI now enters a new phase: deployment in hospitals, with plans to expand into broader reproductive health areas. The reality of building in healthcare requires patience, discipline, and a willingness to navigate uncertainty. But for those who succeed, the impact on patient care is profound. FAQs Q1: What is BioticsAI? BioticsAI is a healthcare AI startup that develops an AI copilot for ultrasound to detect fetal abnormalities. Q2: When did BioticsAI receive FDA approval? BioticsAI received FDA approval in January, allowing the company to deploy its technology in hospitals. Q3: How did BioticsAI approach FDA approval? The startup integrated clinical validation, regulatory strategy, and product development from day one, working closely with clinicians and regulators. Q4: What fundraising challenges did BioticsAI face? Investors were concerned about FDA risk. The startup built an early prototype for under $100,000 and won Bitcoin World Startup Battlefield in 2023 to gain credibility. Q5: How does BioticsAI keep its team motivated? By building a culture of alignment and celebrating small wins on the R&D side, such as clinical studies and healthcare partnerships. This post FDA Approval and Fundraising: BioticsAI Founder Reveals the Reality of Building a Healthcare AI Startup first appeared on BitcoinWorld .
